|
gptkbp:instanceOf
|
gptkb:brand
gptkb:drug
|
|
gptkbp:activeIngredient
|
gptkb:follitropin_beta
|
|
gptkbp:administeredBy
|
subcutaneous injection
|
|
gptkbp:approvedBy
|
2004
|
|
gptkbp:ATCCode
|
gptkb:G03GA06
|
|
gptkbp:availableOn
|
cartridge
pen injector
|
|
gptkbp:contraindication
|
pregnancy
primary ovarian failure
hypersensitivity to follitropin beta
|
|
gptkbp:countryOfOperation
|
gptkb:United_States
|
|
gptkbp:FDAapproved
|
yes
|
|
gptkbp:form
|
solution for injection
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Follistim AQ
|
|
gptkbp:indication
|
gptkb:male_hypogonadotropic_hypogonadism
anovulation
controlled ovarian stimulation
|
|
gptkbp:legalStatus
|
Rx-only
|
|
gptkbp:manufacturer
|
gptkb:Merck_&_Co.
|
|
gptkbp:mechanismOfAction
|
stimulates ovarian follicular growth
recombinant human follicle stimulating hormone
|
|
gptkbp:pregnancyCategory
|
X
|
|
gptkbp:prescriptionStatus
|
prescription only
|
|
gptkbp:routeOfAdministration
|
subcutaneous
|
|
gptkbp:sideEffect
|
abdominal pain
headache
injection site reaction
ovarian hyperstimulation syndrome
|
|
gptkbp:storage
|
2-8°C (refrigerated)
|
|
gptkbp:storageAfterOpening
|
room temperature for up to 28 days
|
|
gptkbp:usedFor
|
assisted reproductive technology
ovulation induction
infertility treatment
|
|
gptkbp:bfsParent
|
gptkb:Follistim
gptkb:Organon_(2021_spin-off)
gptkb:Organon_&_Co._(2021)
|
|
gptkbp:bfsLayer
|
6
|